IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients’ outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.
Market Dominance | Explore IQVIA's position as the world's largest Contract Research Organization, offering comprehensive services for drug development and commercialization |
Financial Trajectory | Analysts project EPS of 11.23 for FY1 and 12.38 for FY2, with expectations of reacceleration as multi-year headwinds fade |
Competitive Edge | Delve into IQVIA's proprietary data and technology assets, providing unique insights and efficiency in clinical trials and drug development |
Future Prospects | Learn about IQVIA's potential for valuation re-rating and growth opportunities in Data/AI within the healthcare secto |
Metrics to compare | IQV | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIQVPeersSector | |
---|---|---|---|---|
P/E Ratio | 28.3x | −1.8x | −0.7x | |
PEG Ratio | 1.01 | −0.18 | 0.00 | |
Price/Book | 5.7x | 1.4x | 2.6x | |
Price / LTM Sales | 2.6x | 3.3x | 3.2x | |
Upside (Analyst Target) | 18.6% | 22.8% | 43.9% | |
Fair Value Upside | Unlock | 10.8% | 6.5% | Unlock |